Loading...
Market
What will be the severity of the first major adverse event reported in Walgreens' BARDA Project NextGen study by December 31, 2024?
2
Resolution / Starting Odds
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
Official announcement from Walgreens or HHS
Story
HHS Announces Walgreens' BARDA Award for COVID-19 Decentralized Clinical Study Under Project NextGen
Jul 23, 2024, 01:01 PM
Walgreens has received the BARDA Project NextGen Award to conduct a novel COVID-19 decentralized clinical study. The study, which is part of a Phase IV trial, will be carried out in partnership with the RRPV Consortium and will focus on a US FDA authorized or approved COVID-19 vaccine. The trial aims to identify correlates of protection for COVID vaccines and will take place at approximately 20 Walgreens sites, ranging from urban to rural locations. HHS announces the pharmacy-based clinical trial under Project NextGen.
View original story
Similar markets
AE rate < 20% • 25%
AE rate 20-30% • 25%
AE rate 30-40% • 25%
AE rate > 40% • 25%
None reported • 25%
Few minor events • 25%
Significant events • 25%
Major public health concern • 25%
Attributed to vaccine • 25%
Attributed to unrelated causes • 25%
Inconclusive • 25%
No further information released • 25%
Less than 20% • 25%
20% to 25% • 25%
25% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Fully ready • 25%
Partially ready • 25%
Not ready • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Positive • 25%
Negative • 25%
Mixed • 25%
Not published • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Less than 50 • 25%
50 to 100 • 25%
100 to 200 • 25%
More than 200 • 25%
Yes • 50%
No • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%